Traws Pharma Q1 net loss $7.1M; secures up to $60M PIPE financing

Traws Pharma, Inc.

Net loss of $7.1M ($0.53/share) vs net income of $21.5M in Q1 2025; revenue $0.
R&D expense $4.9M (up 96% YoY) on antiviral trial milestones; cash $3.1M at March 31.
Up to $60M private placement closed April 15 with $10M upfront, expected to fund ops into Q1 2027.
TXM influenza prophylaxis advancing to human challenge trial in Q2 2026; FDA clinical hold unresolved.
New hantavirus program initiated; no approved treatments exist for this disease.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Traws Pharma, Inc. reported for the quarter ended March 31, 2026 results: revenue $0.0 million, net income $7.1 million, EPS $0.53.

Period: for the quarter ended March 31, 2026
Revenue: $0.0 million
Net income: $7.1 million
EPS: $0.53
Result: reported results

Exact text from the filing

milestone-based warrants, is sufficient to support planned expenses, including completion of the Challenge Study, into Q1 2027. Revenue for the quarter ended March 31, 2026, was $0.0 million, compared to $0.06 million for the comparable period in 2025. Research and development (R&D) expense for the quarter ended March 31, 2026, totaled $4.9 million, compared to $2.5

View on SEC.gov

Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-061771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.